Skip to main content
. Author manuscript; available in PMC: 2022 Jun 27.
Published in final edited form as: Cancer Res Commun. 2021 Dec;1(3):127–139. doi: 10.1158/2767-9764.CRC-21-0020

Fig. 3. Chordoma cell susceptibility to killing by healthy donor NK cells is enhanced by cetuximab (anti-EGFR) and combination treatment with N-803 (IL-15 superagonist) and cetuximab.

Fig. 3.

Six chordoma cell lines (UM-Chor1, MUG-CC1, UM-Chor5, JHC7, U-CH1, U-CH2) were used as targets for healthy donor NK cells in 111In-release killing assays. (A) Cetuximab-mediated ADCC assays were performed by co-incubating chordoma cells with N-601 or isotype control antibody. NK cells were treated with anti-CD-16 antibody where indicated. (B) Combination treatment assays were performed by co-incubating chordoma cells with cetuximab or isotype control antibody and treating NK cells with N-803 and/or anti-CD-16 antibody where indicated. All E:T ratios are 20:1. Statistical analyses were done by one-way ANOVA with Tukey’s multiple comparisons test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Results shown are the means ± SEM of technical triplicate measurements and are representative of three independent experiments.